About: Feasibility of Long-Term Proteasome Inhibition in Multiple Myeloma by In-Class Transition from Bortezomib to Ixazomib

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Feasibility of Long-Term Proteasome Inhibition in Multiple Myeloma by In-Class Transition from Bortezomib to Ixazomib Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Feasibility of Long-Term Proteasome Inhibition in Multiple Myeloma by In-Class Transition from Bortezomib to Ixazomib
Creator	Aiello, Jack Birhiray, Ruemu Boccia, Ralph Bogard, Kimberly Charu, Veena Cherepanov, Dasha Demers, Brittany Ferrari, Renda Girnius, Saulius Jhangiani, Haresh Kambhampati, Suman Lu, Vickie Lyons, Roger Manda, Sudhir Noga, Stephen Rifkin, Robert Whidden, Presley Yasenchak, Christopher Yimer, Habte Birhiray, Kambhampati Ca, Yasenchak Demers, Cherepanov Ha, Yimer Rh, Ferrari Sj, Noga
Source	Elsevier; PMC
abstract	BACKGROUND: The ongoing US MM-6 study is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) with the aim of increasing proteasome inhibitor (PI)-based treatment adherence/duration while maintaining quality of life (QoL) and improving outcomes. PATIENTS AND METHODS: US community sites are enrolling non-transplant-eligible newly diagnosed multiple myeloma (MM) patients with no evidence of progressive disease after 3 cycles of bortezomib-based therapy to receive ixazomib-Rd (up to 39 cycles or until progression/toxicity). Patients use mobile/wearable digital devices to collect actigraphy (activity/sleep) data and electronically complete QoL/treatment satisfaction/medication adherence questionnaires. Primary endpoint: progression-free survival (PFS); key secondary endpoints include response rates and therapy duration. RESULTS: At data cutoff, 84 patients had been treated (median age 73 years; 44% ≥ 75 years; 49% male; 15% black/African American; 10% Hispanic/Latino); 62% of patients remain on therapy. Mean duration of total PI therapy was 10.1 months and of ixazomib-Rd was 7.3 months. With 8 months median follow-up, 12-month PFS rate was 86% (95% confidence interval, 73–93) from both the start of bortezomib-based treatment and the start of ixazomib-Rd. Overall response rate was 62% (complete response [CR], 4%; very good partial response [VGPR], 25%; partial response [PR], 33%) after bortezomib-based induction and 70% (CR, 26%; VGPR, 29%; PR, 15%) after iCT. The ixazomib-Rd safety profile was consistent with previous clinical trial data. QoL/treatment satisfaction were maintained. CONCLUSION: US MM-6 patients are representative of the real-world US MM population; iCT may permit prolonged PI-based therapy with promising efficacy, without impacting patients’ QoL/treatment satisfaction.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.1016/j.clml.2020.06.024
has license	no-cc
sha1sum (hex)	a4a9ede61b0d50df4e530302414ed425d19bc312
schema:url	https://doi.org/10.1016/j.clml.2020.06.024
resource representing a document's title	Feasibility of Long-Term Proteasome Inhibition in Multiple Myeloma by In-Class Transition from Bortezomib to Ixazomib
has PubMed Central identifier	PMC7336931
schema:publication	Clin Lymphoma Myeloma Leuk
resource representing a document's body	covid:a4a9ede61b0d50df4e530302414ed425d19bc312#body_text
is schema:about of	named entity 'Transition' named entity 'Bortezomib' named entity 'randomized controlled trials' named entity 'Takeda' named entity 'elderly patients' named entity 'clinical trials' named entity 'ixazomib' named entity 'parenteral' named entity 'Takeda' named entity 'immunophenotypic' named entity 'bortezomib' named entity 'EORTC' named entity 'ePRO' named entity 'PFS' named entity 'cycle 8' named entity 'ixazomib' named entity 'HRQoL' named entity 'medication adherence' named entity 'medication adherence' named entity 'cycle 8' named entity 'bortezomib' named entity 'melphalan' named entity 'medication adherence' named entity 'dexamethasone' named entity 'bortezomib' named entity 'dexamethasone' named entity 'actigraphy' named entity 'clinical trials' named entity 'oncology' named entity 'lenalidomide' named entity 'comorbidities' named entity 'older age' named entity 'health-related quality of life' named entity 'ixazomib' named entity 'older age' named entity 'bortezomib' named entity 'ePRO' named entity 'Data analysis' named entity 'EORTC' named entity 'Bortezomib' named entity 'ORR' named entity 'renal impairment' named entity 'clinical practice' named entity 'diarrhea' named entity 'actigraphy' named entity 'thrombocytopenia' named entity 'neutropenia' named entity 'medication adherence' named entity 'clinical trials' named entity '95% confidence interval' named entity 'medication adherence' named entity 'HRQoL' named entity 'AEs' named entity 'btz' named entity 'study design' named entity 'dexamethasone' named entity 'surgical procedures' named entity 'boron' named entity 'clinical trials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software